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Summary Molecular monitoring by the polymerase chain reaction was used to detect and follow minimal
disease in working formulation category B and C on non-Hodgkin's lymphoma. Rearrangement of the bcl-2
gene served as the target for gene amplification. Thirty patients were studied. Bone marrow histology was
compared to PCR analysis of bone marrow aspirate and blood. PCR upstaged disease status in approximately
50% of patients. Results are shown from a patient whose disease was followed with PCR during
chemotherapy from initial remission to relapse. We conclude that PCR of bone marrow and blood can be used
to upstage disease status in low grade lymphoma and PCR of blood may be used to monitor response to
treatment with obvious patient benefit. The general approach of molecular monitoring provides a means for
appraising therapies in the setting of subclinical disease.
Low grade non-Hodgkin's lymphoma (NHL) is as yet an
incurable malignancy (Kalter et al., 1987; Schein et al., 1975;
Horning & Rosenberg, 1984). Initial therapy may produce a
complete remission but the high rate of recurrence indicates
minimal disease persists. In at least 80% of the low grade
NHLs encompassed by categories B and C of the working
formulation, rearrangement of the bc1-2 proto-oncogene
(Figure 1) as part of the 14;18 translocation (Yunis et al.,
1982) generates a suitable target for enzymatic amplification
using the polymerase chain reaction (PCR). The breakpoints
on chromosome 18 involving bcl-2 are clustered mainly at
two sites. Fifty to sixty per cent are found in the major
breakpoint region (MBR) which lies in the 3' untranslated
portion of the gene while a further 25-40% occur in the
minor cluster region (MCR) located in an intron 20 kb down
stream (Cleary et al., 1986a; Weiss et al., 1987). The rear-
rangement brings bcl-2 into conjunction with one of the
joining (JH) gens of the immunoglobulin heavy chain locus
on chromosome 14. The resulting bcl-2/JH DNA sequence is
unique to the malignant clone. The use of this sequence as a
target for amplification by PCR in the detection of minimal
residual disease has been demonstrated (Lee et al., 1987;
Crescenzi et al., 1988; Stetler-Stevenson et al., 1988; Cunning-
ham et al., 1989). In this report we have evaluated the utility
of PCR for monitoring disease status in low grade NHL by
comparing conventional bone marrow histology with PCR
analysis of bone marrow and peripheral blood.
Methods
Bone marrow aspirates, trephines and contemporaneous
peripheral blood were available from 30 patients with a
diagnosis of working formulation category B or C non-
Hodgkin's lymphoma. Infiltration of the bone marrow
trephines was determined by routine histology.
DNA preparation
The extreme sensitivity of PCR coupled with the high
molarity of 'positive' PCR product necessitates strict separa-
tion in the stages in the process of sample analysis from
sample collection to Southern blotting, so as to prevent
contamination between samples and the consequential false
positive results. To this end the following procedure was
adhered to: all glass and plastic ware and solutions were
autoclaved prior to use; in room 1, in a pre-cleaned laminar
flow cabinet, reaction ingredients were aliquoted and
dispensed using pipettes that were never brought into contact
with DNA; a washed pipette was used to dispense DNA and
a 'dummy' addition of DNA to the first and last tubes was
performed; thermocycling and gel electrophoresis were con-
ducted in room 2, pipettes used in this room never enter
room 1. Mononuclear cells were extracted from bone marrow
aspirates (usually 2 ml) and peripheral blood (15 ml) by
centrifugation at 400 g for 30 min on LymphoprepTM
(Nycomed AS, Norway). The mononuclear cells were washed
twice in ice cold PBS then in red cell lysis buffer (0.32 M
sucrose, 10 mM Tris-HCl pH 7.5, 5 mM MgCl2 1% Triton X)
and pelleted. DNA was isolated either by phenol-chloroform
extraction and ethanol precipitation or by resuspension in
digestion mix (1 x PCR buffer, 0.25% Tween 20, 0.6 l1 of
10 mg ml-' proteinase K per 100 ,lI) to give a cell count of
2 x I05 cells gl-' and incubated at 55'C for 3 h or overnight.
The proteinase K was inactivated by heating at 95'C for
15 min.
PCR
All reactions were set up on ice. Five ILI (1 tg) of DNA was
added to 45 Al previously dispensed reaction mix to give a
final concentration of 1.5 mM MgCI2, 50 mM KCI, 10 mM
Tris-HCl pH 8.3, 0.25% Tween 20 and 2.5 units amplitaqTM
(Perkin-Elmer/Cetus, Norwalk CT), 200 IAM NTPs and 5011M
each oligonucleotide primers (British Biotechnology, Oxford,
UK). The primer sequences are shown in Figure 1. Each set
of reactions included two negatives without DNA, placental
DNA (1 pg) and a positive control - for the MBR; SUDHL4
(0.1 fig) a cell line with a characterised bct-2 rearrangement
through the MBR (Cleary et al., 1986b), for the MCR; 0.1 g
DNA from a low grade NHL for which we have sequenced
the breakpoint. After an initial denaturation step at 95°C for
2 min, 45 cycles were performed with the following para-
meters: for the MBR; 94°C 1 min; 50'C 30 s, 72'C 1 min 30 s,
for the MCR; 94°CF 1 min 550C 2 min, 72°C 3 min (Ngan et
al., 1989). Fifteen gl PCR product was then electrophoresed
on an ethidium bromide stained 1.5% agarose gel; viewed
under ultraviolet light and then Southern blotted onto nylon
and fixed under UV light. Filters were hybridised to the
relevant 5' labelled a32 ATP internal oligonucleotide probe
(sequences shown in Figure 1). The autoradiographs were
exposed overnight at - 700C. Films were then developed and
the filter re-exposed over 5 days at - 70°C. When PCR was
negative, the quality of the DNA for PCR was checked by
amplification of the B-globin gene using primers PCO3 and
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PCO4 described elsewhere (Saiki et al., 1988). In addition to
increasing sensitivity, the use of an internal oligonucleotide
probe demonstrates that the PCR product is authentic and
results from amplification across a bcl-2/JH junction. Authen-
ticity was also demonstrated when necessary by direct
sequencing using the dideoxy chain termination method.
Briefly, DNA was purified from the PCR product by phenol-
chloriform extraction, passage down a Sephadex G50 col-
umn, ethanol precipitation and suspension in distilled water.
Oligonucleotides used for probing (Figure 1) served as sequen-
cing primers for Sequenase (USB, Cleveland, Ohio). The
presence of a blc-2 rearrangement was also verified by
repeating the PCR using a primer directed upstream on bcl-2
(either MBR or MCR) of the blc-2 primer used in the first
reaction along with the JH primer. A PCR product with a
size difference commensurate with the shift in priming loca-
tion on bcl-2 results from specific amplification.
Results
Sensitivity ofPCR
Figure 2 shows the sensitivity of PCR for detecting cells
bearing the bcl-2 rearrangement - in this case with the re-
arrangement through the MBR.
Comparison ofbone marrow histology with PCR analysis of
blood and marrow
Table I summarises the results. Bone marrow histology was
positive (HP) in 15 and negative (HN) in 16. PCR bone
Primers
Table I PCR of marrow and blood relation to marrow histology
Polymerase chain reaction
Marrow Blood
Positive Negative Positive Negative
Marrow histology
Positive 15 12 3 9* 6
Negative 16 7 9 9 7
Total 31
*All patients with PCR positive peripheral blood also were PCR
positive in the bone marrow.
marrow was positive in 12 of the HPs and in seven of the
HNs. PCR blood was positive in nine of the HPs and nine of
the HNs. Primary tumour was unavailable in two of HP
patients and two of the HN patients who were negative on
PCR analysis. It is therefore not known whether these
patients, in fact, had a bcl-2 rearrangement involving the
MBR or MCR. Nine patients were PCR positive (blood
and/or marrow) and HN negative. Two of these were in
complete remission (CR) and the remaining six receiving
chemotherapy (cyclophoshamide, vincristine and pred-
nisolone [CVP] or chlorambucil) and were entering CR.
Figure 3 demonstrates the application of molecular
monitoring of response to treatment for a patient with a
stage IIIB low grade NHL receiving CVP chemotherapy.
After three courses of chemotherapy the patient had a good
response with resolution of all lymphadenopathy confirmed
by CT scanning although in November the marrow histology
was positive. Note negative PCR blood in early January. In
late January PCR blood was again positive and by early
February the patient had clinically relapsed. (The difference
in the blood and marrow signals for November probably
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Discussion
In this study we demonstrate how the application ofmolecular
monitoring can add to the assessment of a patient's disease
status.
When bone marrow histology was negative, PCR demon-
strated malignant cells in approximately 50% of both bone
marrow and peripheral blood samples. Using PCR it was
possible to follow a patient's disease into remission and then
detect the presence of subclinical disease - a 'molecular
relapse'. PCR analysis of blood enables a high rate of disease
detection. This indicates it is an effective means for monitor-
ing response to treatment and could be used as an adjunct to
analysis of the bone marrow thereby reducing the need for
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Figure 2 An autoradiograph of a Southern blot of PCR product
probed for bcl-2 rearrangement through the MBR. SUDHL4
cells were serially diluted in peripheral blood lymphocytes (PBLs)
from a healthy donor. After 18 h exposure bands of the expected
size are seen at a dilution of 20 SUDHL4 cells in a background
of 106 PBLs. After 5 days exposure a band was clearly visible at a
dilution of 2 SUDHL4 cells/106 PBLs (autoradiograph not
shown). M = marker. N = negative control, No DNA. P = placenta.
PBL = 106 peripheral blood lymphocytes. 2,20,2 x 102, 2 x l03 =
number of SUDHL4 cells/106 PBLs. S = 1 iLg SUDHL4 DNA.
Figure 3 Molecular monitoring of response to treatment. An
autoradiograph (5 days exposure) of a Southern blot of PCR
products of samples of blood and marrow from a patient with a
stage IIIB low grade lymphoma receiving CVP chemotherapy.
The PCR products were collected from separate experiments.
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repeated bone marrow trephine and aspirate: clearly advan-
tageous to the patient.
When the marrow histology was positive, PCR analysis of
the marrow was positive in 80% and PCR analysis of
peripheral blood was positive in 60%. Of the three patients
for whom bone marrow histology was positive and PCR of
either bone marrow or blood was negative primary tumour
was unavailable in two patients and so it is unknown if their
tumour carries a bcl-2 rearrangement involving the MBR or
MCR. This highlights the need for other targets for
amplification in low grade NHL since some 10-15% of
tumours do not have a bcl-2 rearrangement involving the
MBR or MCR. One target that may prove suitable is the
rearranged variable gene of the immunoglobulin heavy chain
locus (Deane & Norton, 1990; Yamada et al., 1990).
With current therapies relapse in low grade NHL is almost
inevitable. We and others are conducting studies on the role
ofmaintenance therapy in prolonging remission in low grade
NHL. Intriguingly, recently PCR has been used to detect
circulating lymphoma cells in seven of eight patients in con-
tinuous clinical remission for more than 10 years after pre-
senting with advanced follicular low grade NHL (Price et al.,
1991). The explanation for this finding is uncertain (Sklar,
1991) but in the small group of patients who are long-term
survivors with this malignancy detection of minimal residual
disease may have little clinical value. In this context
molecular monitoring should clarify the natural history of
patients in complete remission but PCR positive and reveal
the effectiveness of maintenance therapies on subclinical
disease. This information is likely to influence decisions
about treatment strategies, for example the use of biological
therapies which may be most effective in minimal disease.
The detection ofminimal disease is possible whenever there
is a distinctive DNA/RNA target for PCR (Morgan et al.,
1989; Shiramizu & Magrath, 1990). The implementation of
molecular monitoring therefore offers a general approach for
improving treatment strategies.
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